Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report)’s share price hit a new 52-week high on Friday . The stock traded as high as $8.00 and last traded at $7.88, with a volume of 341944 shares changing hands. The stock had previously closed at $7.77.
Analyst Ratings Changes
A number of research analysts have issued reports on the company. Truist Financial reiterated a “buy” rating and set a $9.00 price target (up previously from $7.00) on shares of Amneal Pharmaceuticals in a research report on Monday, May 6th. The Goldman Sachs Group increased their price objective on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a “buy” rating in a report on Monday, May 6th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $8.25.
Check Out Our Latest Stock Analysis on AMRX
Amneal Pharmaceuticals Price Performance
Institutional Investors Weigh In On Amneal Pharmaceuticals
Several hedge funds have recently modified their holdings of AMRX. ProShare Advisors LLC boosted its stake in shares of Amneal Pharmaceuticals by 8.6% during the 1st quarter. ProShare Advisors LLC now owns 21,902 shares of the company’s stock valued at $133,000 after buying an additional 1,726 shares during the period. SG Americas Securities LLC raised its stake in shares of Amneal Pharmaceuticals by 18.8% in the 1st quarter. SG Americas Securities LLC now owns 20,112 shares of the company’s stock valued at $122,000 after acquiring an additional 3,177 shares in the last quarter. Rothschild Investment LLC bought a new stake in Amneal Pharmaceuticals during the second quarter worth approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Amneal Pharmaceuticals by 13.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after buying an additional 4,115 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Amneal Pharmaceuticals by 6.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 81,264 shares of the company’s stock worth $493,000 after buying an additional 5,146 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Recommended Stories
- Five stocks we like better than Amneal Pharmaceuticals
- What is a buyback in stocks? A comprehensive guide for investors
- Buy the Dip in e.l.f. Beauty: Analysts Point to a New High
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Is Dell’s Stock Plunge a Once-in-a-Lifetime Buying Opportunity?
- Business Services Stocks Investing
- Why Analysts Still Predict Double-Digit Upside for Mosaic Stock
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.